Drug Profile
Darbepoetin alfa biosimilar - HK inno.N
Alternative Names: CJ-40001; YLB217Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator CJ HealthCare
- Developer HK inno.N; YL Biologics
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Anaemia
Highest Development Phases
- Phase III Anaemia
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in Anaemia in Japan (IV, Injection)
- 18 Jun 2020 CJ HealthCare is now called HK inno.N
- 28 Jun 2018 No recent reports of development identified for phase-I development in Anaemia(In volunteers) in South Korea (IV, Injection)